Sera Prognostics develops blood tests that are predictive of preterm birth, preeclampsia, and other pregnancy complications.
Industries BiotechnologyHealth CareHospitalMedicalMedical DeviceHeadquarters Regions Western US Founded Date 2008 Founders Dennis Farrar, Sean Esplin, Steven Graves Operating Status Active Last Funding Type Series E Legal Name Sera Prognostics, Inc.
Stock Symbol NASDAQ:SERA Company Type For Profit
Contact Email info@seraprognostics.com Phone Number 801-990-0520
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative
diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.